<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Pharmacol Rev</journal-id>
<journal-id journal-id-type="iso-abbrev">Pharmacol. Rev</journal-id>
<journal-id journal-id-type="hwp">pharmrev</journal-id>
<journal-id journal-id-type="pmc">Pharmacol Rev</journal-id>
<journal-id journal-id-type="publisher-id">PharmRev</journal-id>
<journal-title-group>
<journal-title>Pharmacological Reviews</journal-title>
</journal-title-group>
<issn pub-type="ppub">0031-6997</issn>
<issn pub-type="epub">1521-0081</issn>
<publisher>
<publisher-name>The American Society for Pharmacology and Experimental Therapeutics</publisher-name>
<publisher-loc>Bethesda, MD</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27363441</article-id>
<article-id pub-id-type="pmc">4931870</article-id>
<article-id pub-id-type="publisher-id">PHARMREV_012484</article-id>
<article-id pub-id-type="doi">10.1124/pr.116.012484</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Nucleus Accumbens: Mechanisms of Addiction across Drug Classes Reflect the Importance of Glutamate Homeostasis</article-title>
<alt-title alt-title-type="short">The Nucleus Accumbens: Mechanisms of Addiction</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Scofield</surname>
<given-names>M. D.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Heinsbroek</surname>
<given-names>J. A.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gipson</surname>
<given-names>C. D.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kupchik</surname>
<given-names>Y. M.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Spencer</surname>
<given-names>S.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Smith</surname>
<given-names>A. C. W.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Roberts-Wolfe</surname>
<given-names>D.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kalivas</surname>
<given-names>P. W.</given-names>
</name>
</contrib>
<aff id="aff1">Department of Neuroscience, Medical University of South Carolina, Charleston, South Carolina (M.D.S., J.A.H., S.S., D.R.-W., P.W.K.); Department of Psychology, Arizona State University, Tempe, Arizona (C.D.G.); Department of Neuroscience, Hebrew University, Jerusalem, Israel (Y.M.K.); and Department of Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai, New York, New York (A.C.W.S.)</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="editor">
<name>
<surname>Witkin</surname>
<given-names>Jeffrey M.</given-names>
</name>
<role>ASSOCIATE EDITOR</role>
</contrib>
</contrib-group>
<author-notes>
<corresp id="cor1"><bold>Address correspondence to:</bold> Dr. Michael D. Scofield, <addr-line>Department of Neuroscience, Medical University of South Carolina, 70 President Street, Charleston, SC 29407.</addr-line> E-mail: <email>scofield@musc.edu</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>7</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<month>7</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>1</day>
<month>7</month>
<year>2017</year>
</pub-date>
<!-- PMC Release delay is 12 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
<volume>68</volume>
<issue>3</issue>
<fpage>816</fpage>
<lpage>871</lpage>
<permissions>
<copyright-statement>Copyright Â© 2016 by The American Society for Pharmacology and Experimental Therapeutics</copyright-statement>
<copyright-year>2016</copyright-year>
</permissions>
<self-uri xlink:href="pr.116.012484.pdf" xlink:title="pdf" xlink:type="simple"></self-uri>
<abstract>
<p>The nucleus accumbens is a major input structure of the basal ganglia and integrates information from cortical and limbic structures to mediate goal-directed behaviors. Chronic exposure to several classes of drugs of abuse disrupts plasticity in this region, allowing drug-associated cues to engender a pathologic motivation for drug seeking. A number of alterations in glutamatergic transmission occur within the nucleus accumbens after withdrawal from chronic drug exposure. These drug-induced neuroadaptations serve as the molecular basis for relapse vulnerability. In this review, we focus on the role that glutamate signal transduction in the nucleus accumbens plays in addiction-related behaviors. First, we explore the nucleus accumbens, including the cell types and neuronal populations present as well as afferent and efferent connections. Next we discuss rodent models of addiction and assess the viability of these models for testing candidate pharmacotherapies for the prevention of relapse. Then we provide a review of the literature describing how synaptic plasticity in the accumbens is altered after exposure to drugs of abuse and withdrawal and also how pharmacological manipulation of glutamate systems in the accumbens can inhibit drug seeking in the laboratory setting. Finally, we examine results from clinical trials in which pharmacotherapies designed to manipulate glutamate systems have been effective in treating relapse in human patients. Further elucidation of how drugs of abuse alter glutamatergic plasticity within the accumbens will be necessary for the development of new therapeutics for the treatment of addiction across all classes of addictive substances.</p>
</abstract>
<counts>
<fig-count count="4"></fig-count>
<table-count count="5"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="715"></ref-count>
<page-count count="56"></page-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name> DJS Export </meta-name>
<meta-value>v1</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
</article>
</pmc-articleset>